Suppr超能文献

瑞吡司特所致药物性日光性荨麻疹

Drug-induced solar urticaria due to repirinast.

作者信息

Kurumaji Y, Shono M

机构信息

Department of Dermatology, Saiseikai Kawaguchi General Hospital, Japan.

出版信息

Dermatology. 1994;188(2):117-21. doi: 10.1159/000247114.

Abstract

We describe the first case of drug-induced solar urticaria due to repirinast, an antiallergic drug developed and introduced into the market in Japan in 1987. The patient was a 72-year-old woman who had been on repirinast for 1 year and 8 months. She developed urticaria immediately after an irradiation with 1.5 J/cm2 of UVA, and the provocation test confirmed that repirinast was responsible for the urticarial reaction. The action spectrum of the urticarial reaction was deduced to be 320-350 nm. Passive and reverse passive transfer test results were both negative. However, intradermal injection of patient serum, obtained while she was on repirinast and irradiated in vitro with UVA, demonstrated positive reactions both in the patient and in a normal volunteer. Our findings suggest that nonallergic mechanisms are involved in the reaction. However, the rarity of the phenomenon also suggests an association with some allergic mechanisms.

摘要

我们描述了首例由瑞吡司特引起的药物性日光性荨麻疹病例。瑞吡司特是一种抗过敏药物,于1987年在日本研发并投放市场。患者为一名72岁女性,服用瑞吡司特已有1年零8个月。她在接受1.5 J/cm2的UVA照射后立即出现荨麻疹,激发试验证实瑞吡司特是导致荨麻疹反应的原因。推断荨麻疹反应的作用光谱为320 - 350 nm。被动和反向被动转移试验结果均为阴性。然而,皮内注射患者在服用瑞吡司特期间采集的血清,并在体外接受UVA照射后,患者和一名正常志愿者均出现阳性反应。我们的研究结果表明该反应涉及非过敏机制。然而,这种现象的罕见性也提示与某些过敏机制有关。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验